Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

A new standard for preventing post-surgery kidney cancer relapse

1

Mar 2026

A new standard for preventing post-surgery kidney cancer relapse

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination regimen that includes belzutifan, a HIF-2α inhibitor, given with standard immune therapy pembrolizumab.

Common cardio drugs proven safe in myeloma patients

1

Mar 2026

Common cardio drugs proven safe in myeloma patients

Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international research.

Investigating microglia’s role in Alzheimer’s pathology

1

Mar 2026

Investigating microglia’s role in Alzheimer’s pathology

Announcing a new article publication for BIO Integration journal. Alzheimer's disease (AD) is a neurodegenerative disorder and the leading cause of dementia worldwide. Microglia, as central nervous system (CNS) resident macrophages, are key to AD pathology. Indeed, microglia aggregation around amyloid-β (Aβ) deposits is an AD hallmark.

Living near nuclear power plants is associated with higher cancer mortality, national US study reports

1

Mar 2026

Living near nuclear power plants is associated with higher cancer mortality, national US study reports

A nationwide ecological study of US counties from 2000 to 2018 found that greater proximity to operational nuclear power plants was associated with higher cancer mortality rates, particularly among adults aged 65–74 years. The analysis used inverse-distance weighting within 200 km and adjusted for demographic, socioeconomic, environmental, and healthcare factors, but did not measure individual radiation exposure.

How zinc deficiency could worsen heart inflammation and what that means for patients

1

Mar 2026

How zinc deficiency could worsen heart inflammation and what that means for patients

This review examines how zinc regulates inflammatory and redox signaling pathways involved in myocarditis and pericarditis, highlighting mechanisms such as NF-κB inhibition and the redox zinc switch. The authors conclude that maintaining optimal zinc status may support cardiovascular resilience, while emphasizing that clinical translation requires further targeted trials.

Higher tyrosine levels linked to shorter lifespan in major UK Biobank analysis

1

Mar 2026

Higher tyrosine levels linked to shorter lifespan in major UK Biobank analysis

Researchers analyzed over 272,000 UK Biobank participants and used Mendelian randomization to investigate whether circulating phenylalanine and tyrosine influence lifespan. Genetically predicted higher tyrosine levels were linked to shorter lifespan, particularly in men, while phenylalanine showed no independent effect after adjustment.

Study maps how NF-κB regulates gene expression in cells

27

Feb 2026

Study maps how NF-κB regulates gene expression in cells

To further the quantitative understanding of cellular decision making, Dr. Gregory Reeves and his team in the chemical engineering department have worked to interpret how a transcription factor dictates the alteration of gene expression in cells.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.